Voyager Therapeutics, Inc.
DIRECTED EVOLUTION

Last updated:

Abstract:

The disclosure provides compositions and methods for the preparation, manufacture, formulation and therapeutic use of adeno-associated virus (AAV) particles for the prevention and/or treatment of diseases.

Status:
Application
Type:

Utility

Filling date:

16 May 2019

Issue date:

15 Jul 2021